Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Stereotactic Radiotherapy for Wet AMD (STAR)

NCT02243878
terminatedphase_3

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757610
completedphase_2

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

NCT02222610
completedphase_3

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292
completedphase_2

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

NCT01251978
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02243878Phase 3

Stereotactic Radiotherapy for Wet AMD (STAR)

Completed
NCT04757610Phase 3

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

Terminated
NCT02222610Phase 2

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

Completed
NCT01748292Phase 3

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

Completed
NCT01251978Phase 2

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Completed
NCT00713518Phase 2

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6